-
The AstraZeneca story
Hear from our employees about AstraZeneca -- who we are, what we do and how we do it. Read more: http://www.astrazeneca.com/About-Us/Features.
-
AstraZeneca - Digital Innovation Group
We realised the big challenges in healthcare required a new approach. So in partnership with AstraZeneca, we created the Digital Innovation Group (DIG), an i...
-
AstraZeneca inaugurates a state of the art Global Technology Center in Chennai
AstraZeneca inaugurates a state of the art Global Technology Center in Chennai
AstraZeneca today inaugurated a new state of the art Global Technology Center (GTC) in Chennai, to develop its world-class IT capability. The establishment of a GTC in Chennai will help improve the IT organization’s efficiency and responsiveness while reducing costs and support 51,500 AstraZeneca employees worldwide.
-
PMQs: Cameron and Miliband on Pfizer AstraZeneca jobs
Labour leader Ed Miliband has called for the prime minister to give assurances on the future of AstraZeneca and possible job losses in Pfizer's bid for the U...
-
AstraZeneca reveals designs for new Global R&D; Centre and Corporate Headquarters in Cambridge, UK
AstraZeneca today revealed the proposed designs for its new Global R&D; Centre and Corporate Headquarters in Cambridge in the UK. The plans for the new facili...
-
AstraZeneca - Recruitment - Dave Smoley CIO
Listen to our Chief Information Officer, Dave Smoley, describe the exciting IT transformation journey happening at AstraZeneca!
-
Employee Recognition at AstraZeneca
When leading global pharmaceutical company AstraZeneca decided to take a fresh look at what it meant to be an 'employer of choice' in its Australian operatio...
-
AstraZeneca Graduate Programme
Learn from AstraZeneca’s students about the exciting opportunities our graduate programmes have to offer. Learn more about how you can join us: http://www.astrazenecacareers.com/students/
-
Pfizer and AstraZeneca: Are These Dinosaurs Mating?
April 28 (Bloomberg) -- Odile Rundquist, senior pharmaceutical analyst at Helvea-Baader Bank, and Bloomberg's Phil Serafino examine Pfizer's renewed interest...
-
AstraZeneca's IMED Biotech Unit
Scientific achievement is full of endeavor and never giving up. Pushing the boundaries of science has led us to where we are today. The human genome project revolutionized medical science—giving the world detailed information about the structure, organization and function of the complete set of human genes. This is been pushing the boundaries of what is possible. At IMED—we share this approach and
-
AstraZeneca and MedImmune: Our Purpose
We push the boundaries of science to deliver life-changing medicines.
-
AstraZeneca - exclusive interview
Find out about the outlook for dividends, its drug pipeline and much more.
-
AstraZeneca Employees use Box to Drive Change through Innovation
Listen to David Smoley, Chief Information Officer, AstraZeneca discuss how Box has enabled the company to reinforce its cloud strategy.
-
AstraZeneca's bucket problem | Lex
► Subscribe to the Financial Times on YouTube: http://bit.ly/FTimeSubs
AstraZeneca has won extended US approval for a pipeline drug but, as Lex's Oliver Ralph and Robert Armstrong discuss, it needs more good news to stem its patent expiration problem.
For more video content from the Financial Times, visit http://www.FT.com/video
Twitter https://twitter.com/ftvideo
Facebook https://www.facebook.
-
Lord Nigel Lawson on Pfizer/AstraZeneca takeover (12May14)
Conservative peer Lord Nigel Lawson talks about the proposed bid by American drugs company Pfizer for British drugs company AstraZeneca. Any picture break up...
-
No deal means both AstraZeneca and Pfizer will lose
Pfizer's fourth and 'final' takeover approach for the UK pharmaceuticals group has been rejected. Lex's Joseph Cotterill and Robert Armstrong discuss where t...
-
MEDICAL - How cholesterol clogs your arteries (atherosclerosis)
To inform on the Atherosclerosis and its complex biological process: it is the idea of this project dedicated to the prevention of the cardiovascular risks o...
-
AstraZeneca Brasil Vídeo Institucional
A AstraZeneca é uma das maiores indústrias farmacêuticas do mundo e se dedica à pesquisa, desenvolvimento, fabricação e comercialização de produtos para vend...
-
Astrazeneca | Take It From A Fish
-
AstraZeneca and MRC to create new UK Centre for Lead Discovery
On 31 March 2014, AstraZeneca and the Medical Research Council (MRC) announced that they have entered into a groundbreaking collaboration aimed at better und...
-
AstraZeneca - Elizabeth
Elizabeth started as pharmaceutical sales specialist at AstraZeneca. She started right out out of college and 6 years later she's a senior sales trainer. You...
-
EO Netwerk reportage: AstraZeneca verzwijgt dodelijke bijwerkingen Seroquel - deel 1
Deel 1/2 De top 3 meest dodelijke antipsychotica (Seroquel, Risperdal en Zyprexa) komt overeen met de top 3 meest voorgeschreven antipsychotica. De moderne a...
-
AstraZeneca Sweden - Mölndal
At AstraZeneca, we know the heart of great pharmaceutical Research and Development (R&D;) is a collection of highly skilled scientists and employees. We have ...
The AstraZeneca story
Hear from our employees about AstraZeneca -- who we are, what we do and how we do it. Read more: http://www.astrazeneca.com/About-Us/Features....
Hear from our employees about AstraZeneca -- who we are, what we do and how we do it. Read more: http://www.astrazeneca.com/About-Us/Features.
wn.com/The Astrazeneca Story
Hear from our employees about AstraZeneca -- who we are, what we do and how we do it. Read more: http://www.astrazeneca.com/About-Us/Features.
- published: 15 Sep 2011
- views: 18171
-
author: astrazeneca
AstraZeneca - Digital Innovation Group
We realised the big challenges in healthcare required a new approach. So in partnership with AstraZeneca, we created the Digital Innovation Group (DIG), an i......
We realised the big challenges in healthcare required a new approach. So in partnership with AstraZeneca, we created the Digital Innovation Group (DIG), an i...
wn.com/Astrazeneca Digital Innovation Group
We realised the big challenges in healthcare required a new approach. So in partnership with AstraZeneca, we created the Digital Innovation Group (DIG), an i...
- published: 20 Jun 2014
- views: 686
-
author: DigitasLBi
AstraZeneca inaugurates a state of the art Global Technology Center in Chennai
AstraZeneca inaugurates a state of the art Global Technology Center in Chennai
AstraZeneca today inaugurated a new state of the art Global Technology Center (G...
AstraZeneca inaugurates a state of the art Global Technology Center in Chennai
AstraZeneca today inaugurated a new state of the art Global Technology Center (GTC) in Chennai, to develop its world-class IT capability. The establishment of a GTC in Chennai will help improve the IT organization’s efficiency and responsiveness while reducing costs and support 51,500 AstraZeneca employees worldwide.
AstraZeneca has significantly invested in this India based IT hub, both in terms of manpower and technology. The center will drive many of the IT tools, technologies and capabilities to that support delivery of AstraZeneca’s strategic ambitions
At the launch event, Mr. David Smoley, Chief Information Officer (CIO), AstraZeneca commented, “The opening of the Global Technology Center marks a key milestone in our journey to develop a world class IT function for AstraZeneca.”
The newly built state of the art center will house in-house IT teams that will help grow our IT technology and operational excellence and provide support to global IT services for AstraZeneca. We’re counting on the talent assembled at this center to help us simplify our support structures and improve our responsiveness to business needs. The centre currently employs 60 people, with the aim of expanding this to approximately 300 in the first year’. AstraZeneca has committed itself to the development of the region by employing locally and will outsource IT services only by exception.”
The company is also looking to develop additional technology centers with a second GTC planned for San Francisco in 2015
wn.com/Astrazeneca Inaugurates A State Of The Art Global Technology Center In Chennai
AstraZeneca inaugurates a state of the art Global Technology Center in Chennai
AstraZeneca today inaugurated a new state of the art Global Technology Center (GTC) in Chennai, to develop its world-class IT capability. The establishment of a GTC in Chennai will help improve the IT organization’s efficiency and responsiveness while reducing costs and support 51,500 AstraZeneca employees worldwide.
AstraZeneca has significantly invested in this India based IT hub, both in terms of manpower and technology. The center will drive many of the IT tools, technologies and capabilities to that support delivery of AstraZeneca’s strategic ambitions
At the launch event, Mr. David Smoley, Chief Information Officer (CIO), AstraZeneca commented, “The opening of the Global Technology Center marks a key milestone in our journey to develop a world class IT function for AstraZeneca.”
The newly built state of the art center will house in-house IT teams that will help grow our IT technology and operational excellence and provide support to global IT services for AstraZeneca. We’re counting on the talent assembled at this center to help us simplify our support structures and improve our responsiveness to business needs. The centre currently employs 60 people, with the aim of expanding this to approximately 300 in the first year’. AstraZeneca has committed itself to the development of the region by employing locally and will outsource IT services only by exception.”
The company is also looking to develop additional technology centers with a second GTC planned for San Francisco in 2015
- published: 16 Sep 2014
- views: 23
PMQs: Cameron and Miliband on Pfizer AstraZeneca jobs
Labour leader Ed Miliband has called for the prime minister to give assurances on the future of AstraZeneca and possible job losses in Pfizer's bid for the U......
Labour leader Ed Miliband has called for the prime minister to give assurances on the future of AstraZeneca and possible job losses in Pfizer's bid for the U...
wn.com/Pmqs Cameron And Miliband On Pfizer Astrazeneca Jobs
Labour leader Ed Miliband has called for the prime minister to give assurances on the future of AstraZeneca and possible job losses in Pfizer's bid for the U...
AstraZeneca reveals designs for new Global R&D; Centre and Corporate Headquarters in Cambridge, UK
AstraZeneca today revealed the proposed designs for its new Global R&D; Centre and Corporate Headquarters in Cambridge in the UK. The plans for the new facili......
AstraZeneca today revealed the proposed designs for its new Global R&D; Centre and Corporate Headquarters in Cambridge in the UK. The plans for the new facili...
wn.com/Astrazeneca Reveals Designs For New Global R D Centre And Corporate Headquarters In Cambridge, UK
AstraZeneca today revealed the proposed designs for its new Global R&D; Centre and Corporate Headquarters in Cambridge in the UK. The plans for the new facili...
AstraZeneca - Recruitment - Dave Smoley CIO
Listen to our Chief Information Officer, Dave Smoley, describe the exciting IT transformation journey happening at AstraZeneca!...
Listen to our Chief Information Officer, Dave Smoley, describe the exciting IT transformation journey happening at AstraZeneca!
wn.com/Astrazeneca Recruitment Dave Smoley Cio
Listen to our Chief Information Officer, Dave Smoley, describe the exciting IT transformation journey happening at AstraZeneca!
- published: 02 Sep 2014
- views: 195
Employee Recognition at AstraZeneca
When leading global pharmaceutical company AstraZeneca decided to take a fresh look at what it meant to be an 'employer of choice' in its Australian operatio......
When leading global pharmaceutical company AstraZeneca decided to take a fresh look at what it meant to be an 'employer of choice' in its Australian operatio...
wn.com/Employee Recognition At Astrazeneca
When leading global pharmaceutical company AstraZeneca decided to take a fresh look at what it meant to be an 'employer of choice' in its Australian operatio...
AstraZeneca Graduate Programme
Learn from AstraZeneca’s students about the exciting opportunities our graduate programmes have to offer. Learn more about how you can join us: http://www.astra...
Learn from AstraZeneca’s students about the exciting opportunities our graduate programmes have to offer. Learn more about how you can join us: http://www.astrazenecacareers.com/students/
wn.com/Astrazeneca Graduate Programme
Learn from AstraZeneca’s students about the exciting opportunities our graduate programmes have to offer. Learn more about how you can join us: http://www.astrazenecacareers.com/students/
- published: 16 Sep 2015
- views: 12
Pfizer and AstraZeneca: Are These Dinosaurs Mating?
April 28 (Bloomberg) -- Odile Rundquist, senior pharmaceutical analyst at Helvea-Baader Bank, and Bloomberg's Phil Serafino examine Pfizer's renewed interest......
April 28 (Bloomberg) -- Odile Rundquist, senior pharmaceutical analyst at Helvea-Baader Bank, and Bloomberg's Phil Serafino examine Pfizer's renewed interest...
wn.com/Pfizer And Astrazeneca Are These Dinosaurs Mating
April 28 (Bloomberg) -- Odile Rundquist, senior pharmaceutical analyst at Helvea-Baader Bank, and Bloomberg's Phil Serafino examine Pfizer's renewed interest...
AstraZeneca's IMED Biotech Unit
Scientific achievement is full of endeavor and never giving up. Pushing the boundaries of science has led us to where we are today. The human genome project rev...
Scientific achievement is full of endeavor and never giving up. Pushing the boundaries of science has led us to where we are today. The human genome project revolutionized medical science—giving the world detailed information about the structure, organization and function of the complete set of human genes. This is been pushing the boundaries of what is possible. At IMED—we share this approach and passion.
Since 2010, we have built upon AstraZeneca’s strong heritage of drug discovery and development to lay the foundations for a bright future. From target identification to the end of phase two trials, our research is focused on our core therapy areas of oncology, respiratory and inflammation, cardiovascular and metabolic disease, while we remain optimistic in neuroscience and infection.
We have built a team of outstanding scientists with diverse experience and a broad range of skills driving forward research to push the boundaries of medical science. We are committed to create an environment that is open for collaboration for our people and our academic and biotech partners for scientific breakthroughs. We are fostering a culture where science thrives, one that is collaborative, agile, dynamic and entrepreneurial.
We have great pride in the breakthroughs we have made, the medicines we have developed, and the lives our science has saved. But the challenges that remain are the most complex and involved. Tackling them requires a new way of thinking. This is how we work, we do it in a way that reflects AstraZeneca’s shared values. It’s how we deliver life changing medicines to patients around the world.
wn.com/Astrazeneca's Imed Biotech Unit
Scientific achievement is full of endeavor and never giving up. Pushing the boundaries of science has led us to where we are today. The human genome project revolutionized medical science—giving the world detailed information about the structure, organization and function of the complete set of human genes. This is been pushing the boundaries of what is possible. At IMED—we share this approach and passion.
Since 2010, we have built upon AstraZeneca’s strong heritage of drug discovery and development to lay the foundations for a bright future. From target identification to the end of phase two trials, our research is focused on our core therapy areas of oncology, respiratory and inflammation, cardiovascular and metabolic disease, while we remain optimistic in neuroscience and infection.
We have built a team of outstanding scientists with diverse experience and a broad range of skills driving forward research to push the boundaries of medical science. We are committed to create an environment that is open for collaboration for our people and our academic and biotech partners for scientific breakthroughs. We are fostering a culture where science thrives, one that is collaborative, agile, dynamic and entrepreneurial.
We have great pride in the breakthroughs we have made, the medicines we have developed, and the lives our science has saved. But the challenges that remain are the most complex and involved. Tackling them requires a new way of thinking. This is how we work, we do it in a way that reflects AstraZeneca’s shared values. It’s how we deliver life changing medicines to patients around the world.
- published: 14 Nov 2014
- views: 7
AstraZeneca and MedImmune: Our Purpose
We push the boundaries of science to deliver life-changing medicines....
We push the boundaries of science to deliver life-changing medicines.
wn.com/Astrazeneca And Medimmune Our Purpose
We push the boundaries of science to deliver life-changing medicines.
- published: 11 Dec 2014
- views: 1128
AstraZeneca - exclusive interview
Find out about the outlook for dividends, its drug pipeline and much more....
Find out about the outlook for dividends, its drug pipeline and much more.
wn.com/Astrazeneca Exclusive Interview
Find out about the outlook for dividends, its drug pipeline and much more.
- published: 30 Oct 2015
- views: 2011
AstraZeneca Employees use Box to Drive Change through Innovation
Listen to David Smoley, Chief Information Officer, AstraZeneca discuss how Box has enabled the company to reinforce its cloud strategy....
Listen to David Smoley, Chief Information Officer, AstraZeneca discuss how Box has enabled the company to reinforce its cloud strategy.
wn.com/Astrazeneca Employees Use Box To Drive Change Through Innovation
Listen to David Smoley, Chief Information Officer, AstraZeneca discuss how Box has enabled the company to reinforce its cloud strategy.
- published: 15 Sep 2015
- views: 266
AstraZeneca's bucket problem | Lex
► Subscribe to the Financial Times on YouTube: http://bit.ly/FTimeSubs
AstraZeneca has won extended US approval for a pipeline drug but, as Lex's Oliver Ralph ...
► Subscribe to the Financial Times on YouTube: http://bit.ly/FTimeSubs
AstraZeneca has won extended US approval for a pipeline drug but, as Lex's Oliver Ralph and Robert Armstrong discuss, it needs more good news to stem its patent expiration problem.
For more video content from the Financial Times, visit http://www.FT.com/video
Twitter https://twitter.com/ftvideo
Facebook https://www.facebook.com/financialtimes
wn.com/Astrazeneca's Bucket Problem | Lex
► Subscribe to the Financial Times on YouTube: http://bit.ly/FTimeSubs
AstraZeneca has won extended US approval for a pipeline drug but, as Lex's Oliver Ralph and Robert Armstrong discuss, it needs more good news to stem its patent expiration problem.
For more video content from the Financial Times, visit http://www.FT.com/video
Twitter https://twitter.com/ftvideo
Facebook https://www.facebook.com/financialtimes
- published: 05 Sep 2015
- views: 355
Lord Nigel Lawson on Pfizer/AstraZeneca takeover (12May14)
Conservative peer Lord Nigel Lawson talks about the proposed bid by American drugs company Pfizer for British drugs company AstraZeneca. Any picture break up......
Conservative peer Lord Nigel Lawson talks about the proposed bid by American drugs company Pfizer for British drugs company AstraZeneca. Any picture break up...
wn.com/Lord Nigel Lawson On Pfizer Astrazeneca Takeover (12May14)
Conservative peer Lord Nigel Lawson talks about the proposed bid by American drugs company Pfizer for British drugs company AstraZeneca. Any picture break up...
No deal means both AstraZeneca and Pfizer will lose
Pfizer's fourth and 'final' takeover approach for the UK pharmaceuticals group has been rejected. Lex's Joseph Cotterill and Robert Armstrong discuss where t......
Pfizer's fourth and 'final' takeover approach for the UK pharmaceuticals group has been rejected. Lex's Joseph Cotterill and Robert Armstrong discuss where t...
wn.com/No Deal Means Both Astrazeneca And Pfizer Will Lose
Pfizer's fourth and 'final' takeover approach for the UK pharmaceuticals group has been rejected. Lex's Joseph Cotterill and Robert Armstrong discuss where t...
MEDICAL - How cholesterol clogs your arteries (atherosclerosis)
To inform on the Atherosclerosis and its complex biological process: it is the idea of this project dedicated to the prevention of the cardiovascular risks o......
To inform on the Atherosclerosis and its complex biological process: it is the idea of this project dedicated to the prevention of the cardiovascular risks o...
wn.com/Medical How Cholesterol Clogs Your Arteries (Atherosclerosis)
To inform on the Atherosclerosis and its complex biological process: it is the idea of this project dedicated to the prevention of the cardiovascular risks o...
- published: 22 Nov 2007
- views: 498433
-
author: technicom3D
AstraZeneca Brasil Vídeo Institucional
A AstraZeneca é uma das maiores indústrias farmacêuticas do mundo e se dedica à pesquisa, desenvolvimento, fabricação e comercialização de produtos para vend......
A AstraZeneca é uma das maiores indústrias farmacêuticas do mundo e se dedica à pesquisa, desenvolvimento, fabricação e comercialização de produtos para vend...
wn.com/Astrazeneca Brasil Vídeo Institucional
A AstraZeneca é uma das maiores indústrias farmacêuticas do mundo e se dedica à pesquisa, desenvolvimento, fabricação e comercialização de produtos para vend...
AstraZeneca and MRC to create new UK Centre for Lead Discovery
On 31 March 2014, AstraZeneca and the Medical Research Council (MRC) announced that they have entered into a groundbreaking collaboration aimed at better und......
On 31 March 2014, AstraZeneca and the Medical Research Council (MRC) announced that they have entered into a groundbreaking collaboration aimed at better und...
wn.com/Astrazeneca And Mrc To Create New UK Centre For Lead Discovery
On 31 March 2014, AstraZeneca and the Medical Research Council (MRC) announced that they have entered into a groundbreaking collaboration aimed at better und...
AstraZeneca - Elizabeth
Elizabeth started as pharmaceutical sales specialist at AstraZeneca. She started right out out of college and 6 years later she's a senior sales trainer. You......
Elizabeth started as pharmaceutical sales specialist at AstraZeneca. She started right out out of college and 6 years later she's a senior sales trainer. You...
wn.com/Astrazeneca Elizabeth
Elizabeth started as pharmaceutical sales specialist at AstraZeneca. She started right out out of college and 6 years later she's a senior sales trainer. You...
EO Netwerk reportage: AstraZeneca verzwijgt dodelijke bijwerkingen Seroquel - deel 1
Deel 1/2 De top 3 meest dodelijke antipsychotica (Seroquel, Risperdal en Zyprexa) komt overeen met de top 3 meest voorgeschreven antipsychotica. De moderne a......
Deel 1/2 De top 3 meest dodelijke antipsychotica (Seroquel, Risperdal en Zyprexa) komt overeen met de top 3 meest voorgeschreven antipsychotica. De moderne a...
wn.com/Eo Netwerk Reportage Astrazeneca Verzwijgt Dodelijke Bijwerkingen Seroquel Deel 1
Deel 1/2 De top 3 meest dodelijke antipsychotica (Seroquel, Risperdal en Zyprexa) komt overeen met de top 3 meest voorgeschreven antipsychotica. De moderne a...
AstraZeneca Sweden - Mölndal
At AstraZeneca, we know the heart of great pharmaceutical Research and Development (R&D;) is a collection of highly skilled scientists and employees. We have ......
At AstraZeneca, we know the heart of great pharmaceutical Research and Development (R&D;) is a collection of highly skilled scientists and employees. We have ...
wn.com/Astrazeneca Sweden Mölndal
At AstraZeneca, we know the heart of great pharmaceutical Research and Development (R&D;) is a collection of highly skilled scientists and employees. We have ...
-
AstraZeneca North West Apprenticeship Programme (UK)
Unsure if University is for you? Apply to one of AstraZeneca's apprenticeship programmes! With opportunities in engineering, technology and more, you'll work alongside our experts while being trained and mentored along the way. http://bit.ly/1TDnmFw
-
Leukemia AstraZeneca Voluntis - MedicalNewsService.com - December 7, 2015
Here are the headlines from MedicalNewsService.com for December 7, 2015.
Targeted Blood Cancer Therapies Offer Significant Improvements In Survival.
New, highly targeted treatment approaches for leukemia, lymphoma, and myeloma were presented today at the 57th American Society of Hematology Annual Meeting representing a tremendous expansion of oral and intravenous therapy options for patients with
-
Precision Pro Events - AstraZeneca 1st Annual Day
Precision Pro Events - AstraZeneca 1st Annual Day
-
NOAV: We Will Stop AstraZeneca's Cambridge Animal Lab And HQ!
It has come to our attention that AstraZeneca's plans for a global headquarters and animal torture lab in Cambridge has been approved. This has displeased us!
AstraZeneca abuses 300,000 animals a year in cruel tests. That's over 800 a day! They kill primates, dogs, rabbits, rodents and other animals. These useless experiments do not help human beings but rather offer AstraZeneca legal protection
-
AstraZeneca
VIDEO FINANCIAL REPORTING
Why invest in is the first financial video platform where you can easily search through thousands of videos describing global securities.
About The Video:
We believe that complex financial data could become more approachable using friendly motion-graphic representation combined with an accurate selection of financial data. To guarantee the most effective information pros
-
IDF and AstraZeneca Q&A; for World Diabetes Day 2015
http://www.worlddiabetesday.org
-
IDF and AstraZeneca Q&A; for World Diabetes Day 2015
Dr. Petra Wilson, Chief Executive Officer of the International Diabetes Federation (IDF) and Mark Mallon, Executive Vice President, International for AstraZeneca, discuss AstraZeneca's partnership on the World Diabetes Day 2015 campaign.
http://www.worlddiabetesday.org
-
Precision Pro Events - Testimonial by Kewyn Walter George, Director AstraZeneca Chennai
Precision Pro Events - Testimonial by Mr.Kewyn Walter George, Director AstraZeneca Chennai
https://www.facebook.com/Precision-Pro-Events-1134096456618346/
https://twitter.com/precision_pro
-
Precision Pro Events - Testimonial by Rajesh Manoharan , HR Communication, AstraZeneca Chennai
Precision Pro Events - Testimonial by Rajesh Manoharan , HR Communication, AstraZeneca Chennai
-
¿Cómo crecer en una empresa? Entrevista a Sofía Videla, HR Director AstraZeneca
¿De quién es la responsabilidad por el desarrollo profesional?¿Qué es más importante: crecer o aprender? Entrevista a Sofía Videla, Directora de RRHH de AstraZeneca
-
Intervista a Gilberto Riggi, Direttore medico di AstraZeneca Italia
-
University of Virginia and AstraZeneca: In search of novel cardiometabolic therapies
We are working with the University of Virginia to develop innovative treatments for cardiovascular disease. The partnership supports preclinical to clinical research projects aimed at identifying disease mechanisms and biological targets with potential to become successful and commercially viable treatments in areas of high unmet medical need.
-
AstraZeneca agrees $2.7bn deal for US biotech firm ZS Pharma
AstraZeneca agrees $2.7bn deal for US biotech firm ZS Pharma : https://youtu.be/EodsC1tdxw4
AstraZeneca has agreed to buy ZS Pharma, the US biotech company, for $2.7bn (£1.8bn) in cash, thwarting the ambitions of a Swiss rival in the deal-hungry pharmaceutical sector.
Britain’s second biggest drugs company followed Thursday’s upbeat annual results by unveiling a $90 a share deal to snap up ZS Ph
-
Charting equities: AstraZeneca rises after results
5 November 2015: IG technical analyst Chris Beauchamp is looking to see if AstraZeneca can get back towards the 200-day moving average of £43.75. He also takes a look at housebuilders who have been heavily hit this week.
-
Astrazeneca 「 Take It From A Fish」 アメリカ
Cannes Lions 2015:ウェルネス部門;グランプリ
売り場に並んだ2匹の魚が、人生や愛などについて語り合いながら、「健康のためにもっと魚を食べたほうがいい」と中性脂肪の数値への注意を促す。
-
Marit Bjørgen avslører sin store hemmelighet til Kowalczyk -- Symbicort, steroider fra «AstraZeneca»
Nazistenes grusomme eksperiment - AstraZeneca sponser professor Kai Håkon Carlsen, Barnemedisinsk avdeling, Rikshospitalet, og hans hustru, Karin C. Lødrup Carlsen, overlege og forskningsleder ved Kvinne- og barneklinikken, Oslo universitetssykehus, for å utføre uhyrlige eksperiment på uskyldige barn | Bjørgens astmamedisin -- northpower1 27.02.11 08:08 Ser at det ble mye oppstyr om Bjørgens astma
-
Pfizer vira-se para a Allergan depois de falhar fusão com a AstraZeneca - economy
A norte-americana Pfizer pode estar em conversações para se fundir com a Allergan, a conhecida fabricante de Botox com sede na Irlanda. As negociações foram reveladas pelo Wall Street Journal e pelo Financial Times, com a Pfizer a recusar comentar, à Reuters, "rumores de mercado e especulações."
A empresa irlandesa, entretanto, confirmou a abordagem. Em comunicado, a farmacêutica irlandesa diz t
-
The AstraZeneca Brand film
What science can do.
-
The AstraZeneca Corporate film
We push the boundaries of science to deliver life-changing medicines.
-
AstraZeneca partnering with HPIC to deliver health and hope
AstraZeneca made this short video to celebrate the mission of HPIC on the occasion of our 25th anniversary. AstraZeneca has been a partner for more than 20 years.
-
AstraZeneca Hope Lodge Commercial (2008).webm
-
AstraZeneca usa DocYouSign para gerar velocidade a sua operação
CIO da AstraZeneca conta como a DocYouSign transformou o negócio da empresa. Hoje 85% dos nossos documentos são assinados via DocYouSign e finalizados em menos de um dia.
AstraZeneca North West Apprenticeship Programme (UK)
Unsure if University is for you? Apply to one of AstraZeneca's apprenticeship programmes! With opportunities in engineering, technology and more, you'll work al...
Unsure if University is for you? Apply to one of AstraZeneca's apprenticeship programmes! With opportunities in engineering, technology and more, you'll work alongside our experts while being trained and mentored along the way. http://bit.ly/1TDnmFw
wn.com/Astrazeneca North West Apprenticeship Programme (Uk)
Unsure if University is for you? Apply to one of AstraZeneca's apprenticeship programmes! With opportunities in engineering, technology and more, you'll work alongside our experts while being trained and mentored along the way. http://bit.ly/1TDnmFw
- published: 10 Dec 2015
- views: 10
Leukemia AstraZeneca Voluntis - MedicalNewsService.com - December 7, 2015
Here are the headlines from MedicalNewsService.com for December 7, 2015.
Targeted Blood Cancer Therapies Offer Significant Improvements In Survival.
New, highly...
Here are the headlines from MedicalNewsService.com for December 7, 2015.
Targeted Blood Cancer Therapies Offer Significant Improvements In Survival.
New, highly targeted treatment approaches for leukemia, lymphoma, and myeloma were presented today at the 57th American Society of Hematology Annual Meeting representing a tremendous expansion of oral and intravenous therapy options for patients with blood cancers.
These treatments show a future for cancer research that is genetically driven and increasingly personalized.
In one promising experimental treatment for acute myeloid leukemia, a specific genetic mutation is targeted – the first genetically driven study for AML for which no new drugs in use have been approved since 1990.
Two studies identified improved options for patients with relapsed or treatment-resistant multiple myeloma. The two therapies, ixazomib and daratumumab, received approval from the FDA this November.
Voluntis And AstraZeneca To Test A Digital Support Service For Treatment For Ovarian Cancer.
The app will be tested as a companion device in three separate clinical trials sponsored by the National Cancer Institute.
Antoine Yver, Head of Oncology, Global Medicines Development at AstraZeneca, said: “Empowering patients with this smartphone-based app gives them greater control of their treatment and management of their response. The support it provides can further reduce medication dose modification and discontinuation rates and help maintain patients on therapy to improve their treatment outcome.”
Pierre Leurent, Chief Executive Officer of Voluntis, said: “We are delighted
to be partnering with AstraZeneca for this project. AstraZeneca has a strong focus on the use of companion devices in drug development. Their approach, combined with our technological, medical and regulatory expertise provides the perfect synergy to create a personalised therapeutic solution that goes beyond the pill to best serve the needs of patients and their health care providers.”
For the full stories, please visit MedicalNewsService.com
wn.com/Leukemia Astrazeneca Voluntis Medicalnewsservice.Com December 7, 2015
Here are the headlines from MedicalNewsService.com for December 7, 2015.
Targeted Blood Cancer Therapies Offer Significant Improvements In Survival.
New, highly targeted treatment approaches for leukemia, lymphoma, and myeloma were presented today at the 57th American Society of Hematology Annual Meeting representing a tremendous expansion of oral and intravenous therapy options for patients with blood cancers.
These treatments show a future for cancer research that is genetically driven and increasingly personalized.
In one promising experimental treatment for acute myeloid leukemia, a specific genetic mutation is targeted – the first genetically driven study for AML for which no new drugs in use have been approved since 1990.
Two studies identified improved options for patients with relapsed or treatment-resistant multiple myeloma. The two therapies, ixazomib and daratumumab, received approval from the FDA this November.
Voluntis And AstraZeneca To Test A Digital Support Service For Treatment For Ovarian Cancer.
The app will be tested as a companion device in three separate clinical trials sponsored by the National Cancer Institute.
Antoine Yver, Head of Oncology, Global Medicines Development at AstraZeneca, said: “Empowering patients with this smartphone-based app gives them greater control of their treatment and management of their response. The support it provides can further reduce medication dose modification and discontinuation rates and help maintain patients on therapy to improve their treatment outcome.”
Pierre Leurent, Chief Executive Officer of Voluntis, said: “We are delighted
to be partnering with AstraZeneca for this project. AstraZeneca has a strong focus on the use of companion devices in drug development. Their approach, combined with our technological, medical and regulatory expertise provides the perfect synergy to create a personalised therapeutic solution that goes beyond the pill to best serve the needs of patients and their health care providers.”
For the full stories, please visit MedicalNewsService.com
- published: 10 Dec 2015
- views: 1
Precision Pro Events - AstraZeneca 1st Annual Day
Precision Pro Events - AstraZeneca 1st Annual Day...
Precision Pro Events - AstraZeneca 1st Annual Day
wn.com/Precision Pro Events Astrazeneca 1St Annual Day
Precision Pro Events - AstraZeneca 1st Annual Day
- published: 26 Nov 2015
- views: 52
NOAV: We Will Stop AstraZeneca's Cambridge Animal Lab And HQ!
It has come to our attention that AstraZeneca's plans for a global headquarters and animal torture lab in Cambridge has been approved. This has displeased us!
...
It has come to our attention that AstraZeneca's plans for a global headquarters and animal torture lab in Cambridge has been approved. This has displeased us!
AstraZeneca abuses 300,000 animals a year in cruel tests. That's over 800 a day! They kill primates, dogs, rabbits, rodents and other animals. These useless experiments do not help human beings but rather offer AstraZeneca legal protection when their drugs go on to harm patients.
Therefore, we intend to stop AstraZeneca from ever building this headquarters and animal torture lab! National Operation Anti-Vivisection will use all lawful means at our disposal to target any and all organisations involved in this project!
There is nowhere to run and there is nowhere to hide! If you have any dealings with AstraZeneca or the building of their lab and HQ, we will find out and we will find you, and (through creative but lawful means) make sure you regret it! You have been warned!
If you have any connection to this development, now is the time to pull out!
If you are an investor, it is time to sell your shares as AstraZeneca is about to become toxic!
National Operation Anti-Vivisection is everyone and no one. We are your children’s teachers, we are your doctors and your nurses, we are your gardeners, your construction workers and your cleaners. We are your friends and neighbours. We are within AstraZeneca and within AstraZeneca's suppliers. We are law abiding citizens and we cannot be stopped!
wn.com/Noav We Will Stop Astrazeneca's Cambridge Animal Lab And Hq
It has come to our attention that AstraZeneca's plans for a global headquarters and animal torture lab in Cambridge has been approved. This has displeased us!
AstraZeneca abuses 300,000 animals a year in cruel tests. That's over 800 a day! They kill primates, dogs, rabbits, rodents and other animals. These useless experiments do not help human beings but rather offer AstraZeneca legal protection when their drugs go on to harm patients.
Therefore, we intend to stop AstraZeneca from ever building this headquarters and animal torture lab! National Operation Anti-Vivisection will use all lawful means at our disposal to target any and all organisations involved in this project!
There is nowhere to run and there is nowhere to hide! If you have any dealings with AstraZeneca or the building of their lab and HQ, we will find out and we will find you, and (through creative but lawful means) make sure you regret it! You have been warned!
If you have any connection to this development, now is the time to pull out!
If you are an investor, it is time to sell your shares as AstraZeneca is about to become toxic!
National Operation Anti-Vivisection is everyone and no one. We are your children’s teachers, we are your doctors and your nurses, we are your gardeners, your construction workers and your cleaners. We are your friends and neighbours. We are within AstraZeneca and within AstraZeneca's suppliers. We are law abiding citizens and we cannot be stopped!
- published: 18 Nov 2015
- views: 3
AstraZeneca
VIDEO FINANCIAL REPORTING
Why invest in is the first financial video platform where you can easily search through thousands of videos describing global securit...
VIDEO FINANCIAL REPORTING
Why invest in is the first financial video platform where you can easily search through thousands of videos describing global securities.
About The Video:
We believe that complex financial data could become more approachable using friendly motion-graphic representation combined with an accurate selection of financial data. To guarantee the most effective information prospective we drew inspiration from Benjamin Graham’s book: “The Intelligent Investor”, a pillar of financial philosophy.
For this project any kind of suggestion or critic will be helpful in order to develop and provide the best service as we can. Please visit our site www.whyinvestin.com and leave a massage to us.
Thank you and hope you'll enjoy.
IMPORTANT INFORMATION - DISCLAIMER
THIS VIDEO IS FOR INFORMATION PURPOSES ONLY AND SHOULD NOT BE RELIED UPON AS INVESTMENT ADVICE. This video has been prepared by Whyinvestin (together with its affiliates, “Whyinvestin”) and is not intended to be taken by, and should not be taken by, any individual recipient as investment advice, a recommendation to buy, hold or sell any security, or an offer to sell or a solicitation of offers to purchase any security.
PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. The performance of the companies discussed on this video is not necessarily indicative of the future performances.
Investors should consider the content of this video in conjunction with investment reports, financial statements and other disclosures regarding the valuations and performance of the specific companies discussed herein.
DO NOT RELY ON ANY OPINIONS, PREDICTIONS OR FORWARD-LOOKING STATEMENTS CONTAINED HEREIN. Certain of the information contained in this video constitutes “forward-looking statements” that are inherently unreliable and actual events or results may differ materially from those reflected or contemplated herein. None of Whyinvestin or any of its representatives makes any assurance as to the accuracy of those predictions or forward-looking statements. Whyinvestin expressly disclaims any obligation or undertaking to update or revise any such forward-looking statements.
EXTERNAL SOURCES. Certain information contained herein has been obtained from third-party sources. Although Whyinvestin believes such sources to be reliable, we make no representation as to its accuracy or completeness.
FINANCIAL DATA. Historical companies’ data, ratios, exchange rate, prices and estimates are provided by Factset research www.factset.com .
Whyinvestin does not verify any data and disclaims any obligation to do so. Whyinvestin, its data or content providers, the financial exchanges and each of their affiliates and business partners (A) expressly disclaim the accuracy, adequacy, or completeness of any data and (B) shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. Neither Whyinvestin nor any of our information providers will be liable for any damages relating to your use of the information provided herein.
Please consult your broker or financial representative to verify pricing before executing any trade. Whyinvestin cannot guarantee the accuracy of the exchange rates used in the videos. You should confirm current rates before making any transactions that could be affected by changes in the exchange rates.
You agree not to copy, modify, reformat, download, store, reproduce, reprocess, transmit or redistribute any data or information found herein or use any such data or information in a commercial enterprise without obtaining prior written consent. Please consult your broker or financial representative to verify pricing before executing any trade.
COPYRIGHT “FAIR USE” Whyinvestin doesn’t own any logo different from the whyinvestin’ s logo contained in the video. The owner of the logos is the subject of the video itself (the company); and all the logos are not authorized by, sponsored by, or associated with the trademark owner .
Whyinvestin uses exclusive rights held by the copyright owner for Educational purposes and for commentary and criticism as part of a news report or published article.
If you are a company, subject of the video and for any reason want to get in contact with Whyinvestin please email:
company@whyinvestin.com
wn.com/Astrazeneca
VIDEO FINANCIAL REPORTING
Why invest in is the first financial video platform where you can easily search through thousands of videos describing global securities.
About The Video:
We believe that complex financial data could become more approachable using friendly motion-graphic representation combined with an accurate selection of financial data. To guarantee the most effective information prospective we drew inspiration from Benjamin Graham’s book: “The Intelligent Investor”, a pillar of financial philosophy.
For this project any kind of suggestion or critic will be helpful in order to develop and provide the best service as we can. Please visit our site www.whyinvestin.com and leave a massage to us.
Thank you and hope you'll enjoy.
IMPORTANT INFORMATION - DISCLAIMER
THIS VIDEO IS FOR INFORMATION PURPOSES ONLY AND SHOULD NOT BE RELIED UPON AS INVESTMENT ADVICE. This video has been prepared by Whyinvestin (together with its affiliates, “Whyinvestin”) and is not intended to be taken by, and should not be taken by, any individual recipient as investment advice, a recommendation to buy, hold or sell any security, or an offer to sell or a solicitation of offers to purchase any security.
PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. The performance of the companies discussed on this video is not necessarily indicative of the future performances.
Investors should consider the content of this video in conjunction with investment reports, financial statements and other disclosures regarding the valuations and performance of the specific companies discussed herein.
DO NOT RELY ON ANY OPINIONS, PREDICTIONS OR FORWARD-LOOKING STATEMENTS CONTAINED HEREIN. Certain of the information contained in this video constitutes “forward-looking statements” that are inherently unreliable and actual events or results may differ materially from those reflected or contemplated herein. None of Whyinvestin or any of its representatives makes any assurance as to the accuracy of those predictions or forward-looking statements. Whyinvestin expressly disclaims any obligation or undertaking to update or revise any such forward-looking statements.
EXTERNAL SOURCES. Certain information contained herein has been obtained from third-party sources. Although Whyinvestin believes such sources to be reliable, we make no representation as to its accuracy or completeness.
FINANCIAL DATA. Historical companies’ data, ratios, exchange rate, prices and estimates are provided by Factset research www.factset.com .
Whyinvestin does not verify any data and disclaims any obligation to do so. Whyinvestin, its data or content providers, the financial exchanges and each of their affiliates and business partners (A) expressly disclaim the accuracy, adequacy, or completeness of any data and (B) shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. Neither Whyinvestin nor any of our information providers will be liable for any damages relating to your use of the information provided herein.
Please consult your broker or financial representative to verify pricing before executing any trade. Whyinvestin cannot guarantee the accuracy of the exchange rates used in the videos. You should confirm current rates before making any transactions that could be affected by changes in the exchange rates.
You agree not to copy, modify, reformat, download, store, reproduce, reprocess, transmit or redistribute any data or information found herein or use any such data or information in a commercial enterprise without obtaining prior written consent. Please consult your broker or financial representative to verify pricing before executing any trade.
COPYRIGHT “FAIR USE” Whyinvestin doesn’t own any logo different from the whyinvestin’ s logo contained in the video. The owner of the logos is the subject of the video itself (the company); and all the logos are not authorized by, sponsored by, or associated with the trademark owner .
Whyinvestin uses exclusive rights held by the copyright owner for Educational purposes and for commentary and criticism as part of a news report or published article.
If you are a company, subject of the video and for any reason want to get in contact with Whyinvestin please email:
company@whyinvestin.com
- published: 17 Nov 2015
- views: 4
IDF and AstraZeneca Q&A; for World Diabetes Day 2015
Dr. Petra Wilson, Chief Executive Officer of the International Diabetes Federation (IDF) and Mark Mallon, Executive Vice President, International for AstraZene...
Dr. Petra Wilson, Chief Executive Officer of the International Diabetes Federation (IDF) and Mark Mallon, Executive Vice President, International for AstraZeneca, discuss AstraZeneca's partnership on the World Diabetes Day 2015 campaign.
http://www.worlddiabetesday.org
wn.com/Idf And Astrazeneca Q A For World Diabetes Day 2015
Dr. Petra Wilson, Chief Executive Officer of the International Diabetes Federation (IDF) and Mark Mallon, Executive Vice President, International for AstraZeneca, discuss AstraZeneca's partnership on the World Diabetes Day 2015 campaign.
http://www.worlddiabetesday.org
- published: 12 Nov 2015
- views: 39
Precision Pro Events - Testimonial by Kewyn Walter George, Director AstraZeneca Chennai
Precision Pro Events - Testimonial by Mr.Kewyn Walter George, Director AstraZeneca Chennai
https://www.facebook.com/Precision-Pro-Events-1134096456618346/
http...
Precision Pro Events - Testimonial by Mr.Kewyn Walter George, Director AstraZeneca Chennai
https://www.facebook.com/Precision-Pro-Events-1134096456618346/
https://twitter.com/precision_pro
wn.com/Precision Pro Events Testimonial By Kewyn Walter George, Director Astrazeneca Chennai
Precision Pro Events - Testimonial by Mr.Kewyn Walter George, Director AstraZeneca Chennai
https://www.facebook.com/Precision-Pro-Events-1134096456618346/
https://twitter.com/precision_pro
- published: 13 Nov 2015
- views: 3
Precision Pro Events - Testimonial by Rajesh Manoharan , HR Communication, AstraZeneca Chennai
Precision Pro Events - Testimonial by Rajesh Manoharan , HR Communication, AstraZeneca Chennai...
Precision Pro Events - Testimonial by Rajesh Manoharan , HR Communication, AstraZeneca Chennai
wn.com/Precision Pro Events Testimonial By Rajesh Manoharan , Hr Communication, Astrazeneca Chennai
Precision Pro Events - Testimonial by Rajesh Manoharan , HR Communication, AstraZeneca Chennai
- published: 13 Nov 2015
- views: 14
¿Cómo crecer en una empresa? Entrevista a Sofía Videla, HR Director AstraZeneca
¿De quién es la responsabilidad por el desarrollo profesional?¿Qué es más importante: crecer o aprender? Entrevista a Sofía Videla, Directora de RRHH de AstraZe...
¿De quién es la responsabilidad por el desarrollo profesional?¿Qué es más importante: crecer o aprender? Entrevista a Sofía Videla, Directora de RRHH de AstraZeneca
wn.com/¿Cómo Crecer En Una Empresa Entrevista A Sofía Videla, Hr Director Astrazeneca
¿De quién es la responsabilidad por el desarrollo profesional?¿Qué es más importante: crecer o aprender? Entrevista a Sofía Videla, Directora de RRHH de AstraZeneca
- published: 11 Nov 2015
- views: 99
University of Virginia and AstraZeneca: In search of novel cardiometabolic therapies
We are working with the University of Virginia to develop innovative treatments for cardiovascular disease. The partnership supports preclinical to clinical res...
We are working with the University of Virginia to develop innovative treatments for cardiovascular disease. The partnership supports preclinical to clinical research projects aimed at identifying disease mechanisms and biological targets with potential to become successful and commercially viable treatments in areas of high unmet medical need.
wn.com/University Of Virginia And Astrazeneca In Search Of Novel Cardiometabolic Therapies
We are working with the University of Virginia to develop innovative treatments for cardiovascular disease. The partnership supports preclinical to clinical research projects aimed at identifying disease mechanisms and biological targets with potential to become successful and commercially viable treatments in areas of high unmet medical need.
- published: 09 Nov 2015
- views: 34
AstraZeneca agrees $2.7bn deal for US biotech firm ZS Pharma
AstraZeneca agrees $2.7bn deal for US biotech firm ZS Pharma : https://youtu.be/EodsC1tdxw4
AstraZeneca has agreed to buy ZS Pharma, the US biotech company, fo...
AstraZeneca agrees $2.7bn deal for US biotech firm ZS Pharma : https://youtu.be/EodsC1tdxw4
AstraZeneca has agreed to buy ZS Pharma, the US biotech company, for $2.7bn (£1.8bn) in cash, thwarting the ambitions of a Swiss rival in the deal-hungry pharmaceutical sector.
Britain’s second biggest drugs company followed Thursday’s upbeat annual results by unveiling a $90 a share deal to snap up ZS Pharma’s technology to develop new treatments for hyperkalemia, or high potassium levels. The condition can result in chronic kidney disease or chronic heart failure.
ZS Pharma’s ZS-9 treatment is under review by the US Food and Drug Administration and could produce sales of more than $1bn a year if approved, AstraZeneca said. The tasteless crystals, mixed with water and taken by mouth, absorb potassium rapidly and flush it out through the digestive system.
Actelion of Switzerland said in September it had started talks with ZS Pharma, based in San Mateo, California, that could have led to a bid. The US company has about 200 employees across three sites in California, Texas and Colorado.
Pascal Soriot, AstraZeneca’s chief executive, said: “Hyperkalemia can be a life-threatening condition for patients with chronic kidney disease and chronic heart failure. However, the risk is underappreciated and prevalence is increasing.
“This acquisition complements our strategic focus on cardiovascular and metabolic disease by adding a potential best in class treatment to our portfolio of innovative medicines.”
The acquisition is part of a deal frenzy sweeping the pharmaceutical sector as companies look to cut costs and buy new treatments to replace ageing drugs whose patents are expiring.
AstraZeneca has made a number of acquisitions to gain specific products and was the subject of a failed £70bn takeover approach by US company Pfizer last year. Pfizer is now in talks with Allergan, the maker of Botox, to form the world’s biggest healthcare business. Dublin-based drug firm Shire has been linked with a number of potential takeovers, including of Radius Health in the US.
wn.com/Astrazeneca Agrees 2.7Bn Deal For US Biotech Firm Zs Pharma
AstraZeneca agrees $2.7bn deal for US biotech firm ZS Pharma : https://youtu.be/EodsC1tdxw4
AstraZeneca has agreed to buy ZS Pharma, the US biotech company, for $2.7bn (£1.8bn) in cash, thwarting the ambitions of a Swiss rival in the deal-hungry pharmaceutical sector.
Britain’s second biggest drugs company followed Thursday’s upbeat annual results by unveiling a $90 a share deal to snap up ZS Pharma’s technology to develop new treatments for hyperkalemia, or high potassium levels. The condition can result in chronic kidney disease or chronic heart failure.
ZS Pharma’s ZS-9 treatment is under review by the US Food and Drug Administration and could produce sales of more than $1bn a year if approved, AstraZeneca said. The tasteless crystals, mixed with water and taken by mouth, absorb potassium rapidly and flush it out through the digestive system.
Actelion of Switzerland said in September it had started talks with ZS Pharma, based in San Mateo, California, that could have led to a bid. The US company has about 200 employees across three sites in California, Texas and Colorado.
Pascal Soriot, AstraZeneca’s chief executive, said: “Hyperkalemia can be a life-threatening condition for patients with chronic kidney disease and chronic heart failure. However, the risk is underappreciated and prevalence is increasing.
“This acquisition complements our strategic focus on cardiovascular and metabolic disease by adding a potential best in class treatment to our portfolio of innovative medicines.”
The acquisition is part of a deal frenzy sweeping the pharmaceutical sector as companies look to cut costs and buy new treatments to replace ageing drugs whose patents are expiring.
AstraZeneca has made a number of acquisitions to gain specific products and was the subject of a failed £70bn takeover approach by US company Pfizer last year. Pfizer is now in talks with Allergan, the maker of Botox, to form the world’s biggest healthcare business. Dublin-based drug firm Shire has been linked with a number of potential takeovers, including of Radius Health in the US.
- published: 06 Nov 2015
- views: 6
Charting equities: AstraZeneca rises after results
5 November 2015: IG technical analyst Chris Beauchamp is looking to see if AstraZeneca can get back towards the 200-day moving average of £43.75. He also takes ...
5 November 2015: IG technical analyst Chris Beauchamp is looking to see if AstraZeneca can get back towards the 200-day moving average of £43.75. He also takes a look at housebuilders who have been heavily hit this week.
wn.com/Charting Equities Astrazeneca Rises After Results
5 November 2015: IG technical analyst Chris Beauchamp is looking to see if AstraZeneca can get back towards the 200-day moving average of £43.75. He also takes a look at housebuilders who have been heavily hit this week.
- published: 05 Nov 2015
- views: 6
Astrazeneca 「 Take It From A Fish」 アメリカ
Cannes Lions 2015:ウェルネス部門;グランプリ
売り場に並んだ2匹の魚が、人生や愛などについて語り合いながら、「健康のためにもっと魚を食べたほうがいい」と中性脂肪の数値への注意を促す。...
Cannes Lions 2015:ウェルネス部門;グランプリ
売り場に並んだ2匹の魚が、人生や愛などについて語り合いながら、「健康のためにもっと魚を食べたほうがいい」と中性脂肪の数値への注意を促す。
wn.com/Astrazeneca 「 Take It From A Fish」 アメリカ
Cannes Lions 2015:ウェルネス部門;グランプリ
売り場に並んだ2匹の魚が、人生や愛などについて語り合いながら、「健康のためにもっと魚を食べたほうがいい」と中性脂肪の数値への注意を促す。
- published: 01 Nov 2015
- views: 3
Marit Bjørgen avslører sin store hemmelighet til Kowalczyk -- Symbicort, steroider fra «AstraZeneca»
Nazistenes grusomme eksperiment - AstraZeneca sponser professor Kai Håkon Carlsen, Barnemedisinsk avdeling, Rikshospitalet, og hans hustru, Karin C. Lødrup Carl...
Nazistenes grusomme eksperiment - AstraZeneca sponser professor Kai Håkon Carlsen, Barnemedisinsk avdeling, Rikshospitalet, og hans hustru, Karin C. Lødrup Carlsen, overlege og forskningsleder ved Kvinne- og barneklinikken, Oslo universitetssykehus, for å utføre uhyrlige eksperiment på uskyldige barn | Bjørgens astmamedisin -- northpower1 27.02.11 08:08 Ser at det ble mye oppstyr om Bjørgens astmamedisin etter gårdagens løp, utenlandsk presse tok straks dette opp igjen.Kanskje ikke så rart da medisinen står på lista som dopingmiddel.Det er visstnok kun Bjørgen som bruker den aktuelle medisinen, mange andre som har astma bruker medisin som er strøket fra lista over dopingmidler.
Så til spørsmålet.
Hvorfor kan ikke Bjørgen bruke astmamedisin av samme sort som andre utøvere med astma bruker?
(Innlegget ble redigert 27.02.11 10:08)
http://vgd.no/sport/vintersport/tema/1635141/tittel/bjoergens-astmamedisin
Carlsen KH. Hvorfor utvikler idrettsutøvere så ofte astma?
Kai-Håkon Carlsen. Barnemedisinsk avdeling. Oslo universitetssykehus, Rikshospitalet. NO-0207 Oslo. k.h.carlsen@medisin.uio.no anstrengelsesutløst
http://www.naaf.no/Documents/1.%20Allergi%20i%20Praksis/2-2012/Aip_2_2012_Hvorfor%20f%C3%A5r%20idrettsutovere_sa_ofte_astma_CarlsenKH.pdf
Hvorfor er vi mer allergiske enn før? | forskning.no
Av: Karin C. Lødrup Carlsen, overlege og forskningsleder ved Kvinne- og barneklinikken, Oslo universitetssykehus | Professor ved Universitetet i Oslo.
http://forskning.no/blogg/forskningssykehuset/hvorfor-er-vi-mer-allergiske-enn
Lung function trajectories from birth through puberty reflect asthma phenotypes with allergic comorbidity
Karin C. Lødrup Carlsen, MD, PhDcorrespondenceemail
, Petter Mowinckel, MSc
, Vegard Hovland, MD
, Geir Håland, MD, PhD
, Amund Riiser, MSc, PhD
, Kai-Håkon Carlsen, MD, PhD
Received: December 1, 2013; Received in revised form: May 18, 2014; Accepted: May 21, 2014; Published Online: July 02, 2014
Background
Childhood asthma phenotypes reflecting underlying developmental mechanisms are sought, with little information on asthma phenotypes based on allergic comorbidities.
Objective
We asked whether lung function trajectories from birth to 16 years were associated with asthma phenotypes with comorbid allergic rhinitis and atopic dermatitis.
This study was performed within the Oslo Research Group of Asthma and Allergy in Childhood; the Lung and Environment (ORAACLE), a member of the Global Asthma and Allergy European Network (GA2LEN) and Mechanisms of the Development of ALLergy (MeDALL), a collaborative project conducted within the European Union under the Health Cooperation Work Programme of the 7th Framework programme (grant agreement no. 261357 ). The Environment and Childhood Asthma study has been funded through the 16 years by the following public funding bodies: The Norwegian Research Council, The Regional Health Board South East, Health and Rehabilitation, the European Union (Global Asthma and Allergy European Network and Mechanisms of the Development of ALLergy projects; MeDALL: grant no. 261357, GA2LEN: FOOD-CT-2004-506378), by unrestricted grants from the Norwegian Association of Asthma and Allergy, Rimi as well as by financing PhD students by the Kloster Foundation and AstraZeneca, and by providing IgE analyses by Thermo-Fisher, Uppsala, Sweden, in collaboration with Fürst Medical Laboratory, Oslo, Norway.
Disclosure of potential conflict of interest: K. C. Lødrup Carlsen has received research support from RegionHealth South East and Thermo Fischer and the Environment and Childhood Asthma study; and has received travel support from MeDALL (MeDALL: grant no. 261357). P. Mowinckel, G. Håland, V. Hovland, and A. Riiser have received research support from RegionHealth South East. K.-H. Carlsen has received research support from RegionHealth South East; is on the boards for Meda Pharmaceutical and Boehringer Ingelheim; and has received lecture fees from Meda Pharmaceuticals, Merck, and Nycomed.
http://www.jacionline.org/article/S0091-6749(14)00731-3/abstract
Nazistenes grusomme eksperiment - Side3
Giftinjeksjoner i øynene og blodige operasjoner uten bedøvelse. For nazilegen Josef Mengele var kz-leiren Auschwitz et laboratorium, og fangene bare forsøksdyr. Dr. Mengele drepte tusenvis av uskyldige mennesker.
http://www.side3.no/historie/nazistenes-grusomme-eksperiment/3423131512.html
Marit Bjørgen hilser til Kowalczyk.mov
Publisert 29.10.2015
http://www.dbtv.no/4585809091001#Marit__Bjorgen_hilser_til_Kowalczykmov
wn.com/Marit Bjørgen Avslører Sin Store Hemmelighet Til Kowalczyk Symbicort, Steroider Fra «Astrazeneca»
Nazistenes grusomme eksperiment - AstraZeneca sponser professor Kai Håkon Carlsen, Barnemedisinsk avdeling, Rikshospitalet, og hans hustru, Karin C. Lødrup Carlsen, overlege og forskningsleder ved Kvinne- og barneklinikken, Oslo universitetssykehus, for å utføre uhyrlige eksperiment på uskyldige barn | Bjørgens astmamedisin -- northpower1 27.02.11 08:08 Ser at det ble mye oppstyr om Bjørgens astmamedisin etter gårdagens løp, utenlandsk presse tok straks dette opp igjen.Kanskje ikke så rart da medisinen står på lista som dopingmiddel.Det er visstnok kun Bjørgen som bruker den aktuelle medisinen, mange andre som har astma bruker medisin som er strøket fra lista over dopingmidler.
Så til spørsmålet.
Hvorfor kan ikke Bjørgen bruke astmamedisin av samme sort som andre utøvere med astma bruker?
(Innlegget ble redigert 27.02.11 10:08)
http://vgd.no/sport/vintersport/tema/1635141/tittel/bjoergens-astmamedisin
Carlsen KH. Hvorfor utvikler idrettsutøvere så ofte astma?
Kai-Håkon Carlsen. Barnemedisinsk avdeling. Oslo universitetssykehus, Rikshospitalet. NO-0207 Oslo. k.h.carlsen@medisin.uio.no anstrengelsesutløst
http://www.naaf.no/Documents/1.%20Allergi%20i%20Praksis/2-2012/Aip_2_2012_Hvorfor%20f%C3%A5r%20idrettsutovere_sa_ofte_astma_CarlsenKH.pdf
Hvorfor er vi mer allergiske enn før? | forskning.no
Av: Karin C. Lødrup Carlsen, overlege og forskningsleder ved Kvinne- og barneklinikken, Oslo universitetssykehus | Professor ved Universitetet i Oslo.
http://forskning.no/blogg/forskningssykehuset/hvorfor-er-vi-mer-allergiske-enn
Lung function trajectories from birth through puberty reflect asthma phenotypes with allergic comorbidity
Karin C. Lødrup Carlsen, MD, PhDcorrespondenceemail
, Petter Mowinckel, MSc
, Vegard Hovland, MD
, Geir Håland, MD, PhD
, Amund Riiser, MSc, PhD
, Kai-Håkon Carlsen, MD, PhD
Received: December 1, 2013; Received in revised form: May 18, 2014; Accepted: May 21, 2014; Published Online: July 02, 2014
Background
Childhood asthma phenotypes reflecting underlying developmental mechanisms are sought, with little information on asthma phenotypes based on allergic comorbidities.
Objective
We asked whether lung function trajectories from birth to 16 years were associated with asthma phenotypes with comorbid allergic rhinitis and atopic dermatitis.
This study was performed within the Oslo Research Group of Asthma and Allergy in Childhood; the Lung and Environment (ORAACLE), a member of the Global Asthma and Allergy European Network (GA2LEN) and Mechanisms of the Development of ALLergy (MeDALL), a collaborative project conducted within the European Union under the Health Cooperation Work Programme of the 7th Framework programme (grant agreement no. 261357 ). The Environment and Childhood Asthma study has been funded through the 16 years by the following public funding bodies: The Norwegian Research Council, The Regional Health Board South East, Health and Rehabilitation, the European Union (Global Asthma and Allergy European Network and Mechanisms of the Development of ALLergy projects; MeDALL: grant no. 261357, GA2LEN: FOOD-CT-2004-506378), by unrestricted grants from the Norwegian Association of Asthma and Allergy, Rimi as well as by financing PhD students by the Kloster Foundation and AstraZeneca, and by providing IgE analyses by Thermo-Fisher, Uppsala, Sweden, in collaboration with Fürst Medical Laboratory, Oslo, Norway.
Disclosure of potential conflict of interest: K. C. Lødrup Carlsen has received research support from RegionHealth South East and Thermo Fischer and the Environment and Childhood Asthma study; and has received travel support from MeDALL (MeDALL: grant no. 261357). P. Mowinckel, G. Håland, V. Hovland, and A. Riiser have received research support from RegionHealth South East. K.-H. Carlsen has received research support from RegionHealth South East; is on the boards for Meda Pharmaceutical and Boehringer Ingelheim; and has received lecture fees from Meda Pharmaceuticals, Merck, and Nycomed.
http://www.jacionline.org/article/S0091-6749(14)00731-3/abstract
Nazistenes grusomme eksperiment - Side3
Giftinjeksjoner i øynene og blodige operasjoner uten bedøvelse. For nazilegen Josef Mengele var kz-leiren Auschwitz et laboratorium, og fangene bare forsøksdyr. Dr. Mengele drepte tusenvis av uskyldige mennesker.
http://www.side3.no/historie/nazistenes-grusomme-eksperiment/3423131512.html
Marit Bjørgen hilser til Kowalczyk.mov
Publisert 29.10.2015
http://www.dbtv.no/4585809091001#Marit__Bjorgen_hilser_til_Kowalczykmov
- published: 29 Oct 2015
- views: 23
Pfizer vira-se para a Allergan depois de falhar fusão com a AstraZeneca - economy
A norte-americana Pfizer pode estar em conversações para se fundir com a Allergan, a conhecida fabricante de Botox com sede na Irlanda. As negociações foram rev...
A norte-americana Pfizer pode estar em conversações para se fundir com a Allergan, a conhecida fabricante de Botox com sede na Irlanda. As negociações foram reveladas pelo Wall Street Journal e pelo Financial Times, com a Pfizer a recusar comentar, à Reuters, "rumores de mercado e especulações."
A empresa irlandesa, entretanto, confirmou a abordagem. Em comunicado, a farmacêutica irlandesa diz ter sido "abordada" e que está "em discussões preliminares e amigáveis sobre uma potencial transação …
LEIA MAIS: http://pt.euronews.com/2015/10/29/pfizer-vira-se-para-a-allergan-depois-de-falhar-fusao-com-a-astrazeneca
euronews: o canal de notícias mais visto na Europa
Subscreva! http://www.youtube.com/subscription_center?add_user=euronewspt
euronews está disponível em 13 línguas: https://www.youtube.com/user/euronewsnetwork/channels
Em português:
Site: http://pt.euronews.com
Facebook: https://www.facebook.com/euronews
Twitter: http://twitter.com/euronewspt
wn.com/Pfizer Vira Se Para A Allergan Depois De Falhar Fusão Com A Astrazeneca Economy
A norte-americana Pfizer pode estar em conversações para se fundir com a Allergan, a conhecida fabricante de Botox com sede na Irlanda. As negociações foram reveladas pelo Wall Street Journal e pelo Financial Times, com a Pfizer a recusar comentar, à Reuters, "rumores de mercado e especulações."
A empresa irlandesa, entretanto, confirmou a abordagem. Em comunicado, a farmacêutica irlandesa diz ter sido "abordada" e que está "em discussões preliminares e amigáveis sobre uma potencial transação …
LEIA MAIS: http://pt.euronews.com/2015/10/29/pfizer-vira-se-para-a-allergan-depois-de-falhar-fusao-com-a-astrazeneca
euronews: o canal de notícias mais visto na Europa
Subscreva! http://www.youtube.com/subscription_center?add_user=euronewspt
euronews está disponível em 13 línguas: https://www.youtube.com/user/euronewsnetwork/channels
Em português:
Site: http://pt.euronews.com
Facebook: https://www.facebook.com/euronews
Twitter: http://twitter.com/euronewspt
- published: 29 Oct 2015
- views: 38
The AstraZeneca Corporate film
We push the boundaries of science to deliver life-changing medicines....
We push the boundaries of science to deliver life-changing medicines.
wn.com/The Astrazeneca Corporate Film
We push the boundaries of science to deliver life-changing medicines.
- published: 26 Oct 2015
- views: 153
AstraZeneca partnering with HPIC to deliver health and hope
AstraZeneca made this short video to celebrate the mission of HPIC on the occasion of our 25th anniversary. AstraZeneca has been a partner for more than 20 year...
AstraZeneca made this short video to celebrate the mission of HPIC on the occasion of our 25th anniversary. AstraZeneca has been a partner for more than 20 years.
wn.com/Astrazeneca Partnering With Hpic To Deliver Health And Hope
AstraZeneca made this short video to celebrate the mission of HPIC on the occasion of our 25th anniversary. AstraZeneca has been a partner for more than 20 years.
- published: 14 Oct 2015
- views: 6
AstraZeneca usa DocYouSign para gerar velocidade a sua operação
CIO da AstraZeneca conta como a DocYouSign transformou o negócio da empresa. Hoje 85% dos nossos documentos são assinados via DocYouSign e finalizados em menos ...
CIO da AstraZeneca conta como a DocYouSign transformou o negócio da empresa. Hoje 85% dos nossos documentos são assinados via DocYouSign e finalizados em menos de um dia.
wn.com/Astrazeneca USA Docyousign Para Gerar Velocidade A Sua Operação
CIO da AstraZeneca conta como a DocYouSign transformou o negócio da empresa. Hoje 85% dos nossos documentos são assinados via DocYouSign e finalizados em menos de um dia.
- published: 07 Oct 2015
- views: 12
-
Så agerar du vid en V-botten, analyser av Volvo, Ericsson, AstraZeneca mfl.
Läs mer om en V-botten här: http://www.borstjanaren.se/borst/borstArticleDetails/article_id/2740
-
Breaching barriers Junctures & junctions in inflammation: AstraZeneca Women in Pharmacology Lecture
Professor Sussan Nourshargh, Queen Mary University of London, delivered the AstraZeneca Women in Pharmacology Prize Lecture 2014: Breaching barriers: Junctures and junctions in inflammation at Pharmacology 2014
-
GuruTalk with Mr.Pankaj Gursahani, Director - Sales Training, AstraZeneca India Pharma Ltd.
The Business Code of Conduct - Join AVAGMAH Online Schools ongoing GuruTalk series to learn how to run businesses ethically from Mr. Pankaj Gursahani, Direct...
-
«Слияние и поглощение». Инвестиционная идея в связи с планами Pfizer приобрести AstraZeneca
-
The Open PHACTS Discovery Platform, Ola Engkvist, AstraZeneca
Länkade Data Nätverksträff / Swedish Linked Data Network Meet-up
-
OMXS30 SP500 Kinnevik AstraZeneca Husqvarna.avi
De amerikanska börserna tuffar på och måndagens positiva reversalformation stärkte köparna under gårdagen. Även om uppgångarna var måttliga på Dow Jones och ...
-
FIPH Account 2014 05 16 Pfizer & AstraZeneca
FIPH Account. Inversión Fundamental en Industria Farmacéutica y sector Health. Información e inversión bursatil, opiniones y formación continuada. FIPH Accou...
-
Political Capital- SEBI Raises Red Flag On AstraZeneca OFS
SEBI's red flag on the way AstraZeneca's offer-for-sale (OFS) has cornered the U.S.- based hedge fund - Elliott Group. The news comes just weeks after anothe...
-
Professor Julia Buckingham, AstraZeneca Women in Pharmacology Prize Lecture 2009
Professor Julia Buckingham delivers the AstraZeneca Women in Pharmacology Prize Lecture 2009: Stress, laughter and a following wind.
-
Thierry Kogej (AstraZeneca): Increase compound collection value via collaborations
Pharmaceutical R&D; is facing increasing pressure such as rising operational costs, depleted pipelines and patent expiries.
In this environment, it is crucial to improve R&D; productivity. This can be achieved by increasing the level of collaboration and partnership between pharmaceutical companies, academia and CROs. Some examples of such collaborations related to the increase of the size and the
-
Concurso Premios Científicos SEC-AstraZeneca “Cuida mi Corazón”
-
DAPT – The Longer the Better? Sponsored by AstraZeneca
-
LEAN projektet på AstraZeneca -Henrik Nordell
Vi fick höra att det nu är läkemedeltillverkarnas tur att drabbas av ett stålbad och om behovet av att effektivisera även inom administrationen. Sedan berätt...
-
ELRIG DD14 Day 1 1400 Susan Galbraith, AstraZeneca
Genetic drivers of cancer growth and resistance mechanisms
-
Jen Groover Speaking at an Astrazeneca Conference
-
Paul Simmonds, ex-CISO, AstraZeneca. Presents @ The 7th Cloud Circle Forum
-
Brico A vs AstraZeneca - Primeiro Tempo
-
AstraZeneca Diabetes Part 2 25 11 35 PocketPC
-
Dave Smoley, ServiceNow Knowledge15 - theCUBE
Dave Smoley, AstraZeneca, at ServiceNow Knowledge15 with John Furrier and Dave Vellante
@theCUBE
#know15
-
Parcours client, parcours patient: l'expérience de service - 12/02/13 - G. Meneux, AstraZeneca(2/4)
Matins de l'Innovation ESSEC-ISIS, 12 février 2013 : Parcours client, parcours patient: l'expérience de service.
La première intervention " Payeurs, prescripteurs, patients : le paradoxe du client" était présentée par Gwenaël Meneux, Directeur Customer Excellence chez AstraZeneca
Les Matins de l'innovation invitent des intervenants issus du monde de l'entreprise ou académiques à partager leurs e
-
Cash investigation - Le business de la peur / intégrale
La menace terroriste est devenue une réalité qui inquiète de nombreux Français. Ce climat de peur fait les affaires du secteur de la sécurité, qui pèse aujourd'hui dix milliards d'euros. «Cash investigation» révèle les dessous de ce business qui a le vent en poupe. Certains industriels sont par exemple prêts à manipuler les statistiques pour faire gonfler leur bénéfices. L'enquête présentée par El
-
Love you Mom :) -Pokemon ORAS: Not Used Enough #49 - AceTrainerTroy
Breast Cancer Awareness Info: http://healthfinder.gov/nho/octobertoolkit.aspx http://www.astrazeneca-us.com/responsibility/astrazeneca-healthcare-foundation
Whats up Trainers Troy back here with Ep. #49 of Not Used Enough. Current Record: 29-31
Smash that Like button to 35 Likes!!
Battle 1 Starts- 5:45
Q&A; Starts- 14:48
Battle 2 Starts- 28:12
▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬
Dont forget to leave a
Så agerar du vid en V-botten, analyser av Volvo, Ericsson, AstraZeneca mfl.
Läs mer om en V-botten här: http://www.borstjanaren.se/borst/borstArticleDetails/article_id/2740...
Läs mer om en V-botten här: http://www.borstjanaren.se/borst/borstArticleDetails/article_id/2740
wn.com/Så Agerar Du Vid En V Botten, Analyser Av Volvo, Ericsson, Astrazeneca Mfl.
Läs mer om en V-botten här: http://www.borstjanaren.se/borst/borstArticleDetails/article_id/2740
- published: 16 Sep 2015
- views: 250
Breaching barriers Junctures & junctions in inflammation: AstraZeneca Women in Pharmacology Lecture
Professor Sussan Nourshargh, Queen Mary University of London, delivered the AstraZeneca Women in Pharmacology Prize Lecture 2014: Breaching barriers: Junctures ...
Professor Sussan Nourshargh, Queen Mary University of London, delivered the AstraZeneca Women in Pharmacology Prize Lecture 2014: Breaching barriers: Junctures and junctions in inflammation at Pharmacology 2014
wn.com/Breaching Barriers Junctures Junctions In Inflammation Astrazeneca Women In Pharmacology Lecture
Professor Sussan Nourshargh, Queen Mary University of London, delivered the AstraZeneca Women in Pharmacology Prize Lecture 2014: Breaching barriers: Junctures and junctions in inflammation at Pharmacology 2014
- published: 05 Feb 2015
- views: 0
GuruTalk with Mr.Pankaj Gursahani, Director - Sales Training, AstraZeneca India Pharma Ltd.
The Business Code of Conduct - Join AVAGMAH Online Schools ongoing GuruTalk series to learn how to run businesses ethically from Mr. Pankaj Gursahani, Direct......
The Business Code of Conduct - Join AVAGMAH Online Schools ongoing GuruTalk series to learn how to run businesses ethically from Mr. Pankaj Gursahani, Direct...
wn.com/Gurutalk With Mr.Pankaj Gursahani, Director Sales Training, Astrazeneca India Pharma Ltd.
The Business Code of Conduct - Join AVAGMAH Online Schools ongoing GuruTalk series to learn how to run businesses ethically from Mr. Pankaj Gursahani, Direct...
The Open PHACTS Discovery Platform, Ola Engkvist, AstraZeneca
Länkade Data Nätverksträff / Swedish Linked Data Network Meet-up...
Länkade Data Nätverksträff / Swedish Linked Data Network Meet-up
wn.com/The Open Phacts Discovery Platform, Ola Engkvist, Astrazeneca
Länkade Data Nätverksträff / Swedish Linked Data Network Meet-up
- published: 29 Apr 2015
- views: 4
OMXS30 SP500 Kinnevik AstraZeneca Husqvarna.avi
De amerikanska börserna tuffar på och måndagens positiva reversalformation stärkte köparna under gårdagen. Även om uppgångarna var måttliga på Dow Jones och ......
De amerikanska börserna tuffar på och måndagens positiva reversalformation stärkte köparna under gårdagen. Även om uppgångarna var måttliga på Dow Jones och ...
wn.com/Omxs30 Sp500 Kinnevik Astrazeneca Husqvarna.Avi
De amerikanska börserna tuffar på och måndagens positiva reversalformation stärkte köparna under gårdagen. Även om uppgångarna var måttliga på Dow Jones och ...
FIPH Account 2014 05 16 Pfizer & AstraZeneca
FIPH Account. Inversión Fundamental en Industria Farmacéutica y sector Health. Información e inversión bursatil, opiniones y formación continuada. FIPH Accou......
FIPH Account. Inversión Fundamental en Industria Farmacéutica y sector Health. Información e inversión bursatil, opiniones y formación continuada. FIPH Accou...
wn.com/Fiph Account 2014 05 16 Pfizer Astrazeneca
FIPH Account. Inversión Fundamental en Industria Farmacéutica y sector Health. Información e inversión bursatil, opiniones y formación continuada. FIPH Accou...
Political Capital- SEBI Raises Red Flag On AstraZeneca OFS
SEBI's red flag on the way AstraZeneca's offer-for-sale (OFS) has cornered the U.S.- based hedge fund - Elliott Group. The news comes just weeks after anothe......
SEBI's red flag on the way AstraZeneca's offer-for-sale (OFS) has cornered the U.S.- based hedge fund - Elliott Group. The news comes just weeks after anothe...
wn.com/Political Capital Sebi Raises Red Flag On Astrazeneca Ofs
SEBI's red flag on the way AstraZeneca's offer-for-sale (OFS) has cornered the U.S.- based hedge fund - Elliott Group. The news comes just weeks after anothe...
Professor Julia Buckingham, AstraZeneca Women in Pharmacology Prize Lecture 2009
Professor Julia Buckingham delivers the AstraZeneca Women in Pharmacology Prize Lecture 2009: Stress, laughter and a following wind....
Professor Julia Buckingham delivers the AstraZeneca Women in Pharmacology Prize Lecture 2009: Stress, laughter and a following wind.
wn.com/Professor Julia Buckingham, Astrazeneca Women In Pharmacology Prize Lecture 2009
Professor Julia Buckingham delivers the AstraZeneca Women in Pharmacology Prize Lecture 2009: Stress, laughter and a following wind.
- published: 11 Jun 2015
- views: 5
Thierry Kogej (AstraZeneca): Increase compound collection value via collaborations
Pharmaceutical R&D; is facing increasing pressure such as rising operational costs, depleted pipelines and patent expiries.
In this environment, it is crucial t...
Pharmaceutical R&D; is facing increasing pressure such as rising operational costs, depleted pipelines and patent expiries.
In this environment, it is crucial to improve R&D; productivity. This can be achieved by increasing the level of collaboration and partnership between pharmaceutical companies, academia and CROs. Some examples of such collaborations related to the increase of the size and the quality of the AstraZeneca screening collection will be presented as well as details on the cheminformatics platform supporting these activities.
wn.com/Thierry Kogej (Astrazeneca) Increase Compound Collection Value Via Collaborations
Pharmaceutical R&D; is facing increasing pressure such as rising operational costs, depleted pipelines and patent expiries.
In this environment, it is crucial to improve R&D; productivity. This can be achieved by increasing the level of collaboration and partnership between pharmaceutical companies, academia and CROs. Some examples of such collaborations related to the increase of the size and the quality of the AstraZeneca screening collection will be presented as well as details on the cheminformatics platform supporting these activities.
- published: 22 Jun 2015
- views: 8
LEAN projektet på AstraZeneca -Henrik Nordell
Vi fick höra att det nu är läkemedeltillverkarnas tur att drabbas av ett stålbad och om behovet av att effektivisera även inom administrationen. Sedan berätt......
Vi fick höra att det nu är läkemedeltillverkarnas tur att drabbas av ett stålbad och om behovet av att effektivisera även inom administrationen. Sedan berätt...
wn.com/Lean Projektet På Astrazeneca Henrik Nordell
Vi fick höra att det nu är läkemedeltillverkarnas tur att drabbas av ett stålbad och om behovet av att effektivisera även inom administrationen. Sedan berätt...
ELRIG DD14 Day 1 1400 Susan Galbraith, AstraZeneca
Genetic drivers of cancer growth and resistance mechanisms...
Genetic drivers of cancer growth and resistance mechanisms
wn.com/Elrig Dd14 Day 1 1400 Susan Galbraith, Astrazeneca
Genetic drivers of cancer growth and resistance mechanisms
- published: 11 Sep 2014
- views: 6
Dave Smoley, ServiceNow Knowledge15 - theCUBE
Dave Smoley, AstraZeneca, at ServiceNow Knowledge15 with John Furrier and Dave Vellante
@theCUBE
#know15...
Dave Smoley, AstraZeneca, at ServiceNow Knowledge15 with John Furrier and Dave Vellante
@theCUBE
#know15
wn.com/Dave Smoley, Servicenow Knowledge15 Thecube
Dave Smoley, AstraZeneca, at ServiceNow Knowledge15 with John Furrier and Dave Vellante
@theCUBE
#know15
- published: 22 Apr 2015
- views: 34
Parcours client, parcours patient: l'expérience de service - 12/02/13 - G. Meneux, AstraZeneca(2/4)
Matins de l'Innovation ESSEC-ISIS, 12 février 2013 : Parcours client, parcours patient: l'expérience de service.
La première intervention " Payeurs, prescripte...
Matins de l'Innovation ESSEC-ISIS, 12 février 2013 : Parcours client, parcours patient: l'expérience de service.
La première intervention " Payeurs, prescripteurs, patients : le paradoxe du client" était présentée par Gwenaël Meneux, Directeur Customer Excellence chez AstraZeneca
Les Matins de l'innovation invitent des intervenants issus du monde de l'entreprise ou académiques à partager leurs expériences sur un sujet autour de l'innovation dans l'économie des services.
wn.com/Parcours Client, Parcours Patient L'Expérience De Service 12 02 13 G. Meneux, Astrazeneca(2 4)
Matins de l'Innovation ESSEC-ISIS, 12 février 2013 : Parcours client, parcours patient: l'expérience de service.
La première intervention " Payeurs, prescripteurs, patients : le paradoxe du client" était présentée par Gwenaël Meneux, Directeur Customer Excellence chez AstraZeneca
Les Matins de l'innovation invitent des intervenants issus du monde de l'entreprise ou académiques à partager leurs expériences sur un sujet autour de l'innovation dans l'économie des services.
- published: 28 Feb 2013
- views: 481
Cash investigation - Le business de la peur / intégrale
La menace terroriste est devenue une réalité qui inquiète de nombreux Français. Ce climat de peur fait les affaires du secteur de la sécurité, qui pèse aujourd'...
La menace terroriste est devenue une réalité qui inquiète de nombreux Français. Ce climat de peur fait les affaires du secteur de la sécurité, qui pèse aujourd'hui dix milliards d'euros. «Cash investigation» révèle les dessous de ce business qui a le vent en poupe. Certains industriels sont par exemple prêts à manipuler les statistiques pour faire gonfler leur bénéfices. L'enquête présentée par Elise Lucet montre également les failles de la biométrie, présentée comme la solution miracle. Gros plan également sur les caméras de surveillance, qui ont envahi le paysage urbain. Plus de 40 000 objectifs surveillent les villes de France et, depuis peu, les petites communes rurales. Mais ces caméras sont-elles vraiment efficace ?
Elise Lucet
France 2
#cashinvestigation
Toutes l'actualité de Cash Investigation
http://www.francetvinfo.fr/replay-magazine/france-2/cash-investigation/
https://www.facebook.com/cashinvestigationfrance2
Twitter: @cashinvestigati
wn.com/Cash Investigation Le Business De La Peur Intégrale
La menace terroriste est devenue une réalité qui inquiète de nombreux Français. Ce climat de peur fait les affaires du secteur de la sécurité, qui pèse aujourd'hui dix milliards d'euros. «Cash investigation» révèle les dessous de ce business qui a le vent en poupe. Certains industriels sont par exemple prêts à manipuler les statistiques pour faire gonfler leur bénéfices. L'enquête présentée par Elise Lucet montre également les failles de la biométrie, présentée comme la solution miracle. Gros plan également sur les caméras de surveillance, qui ont envahi le paysage urbain. Plus de 40 000 objectifs surveillent les villes de France et, depuis peu, les petites communes rurales. Mais ces caméras sont-elles vraiment efficace ?
Elise Lucet
France 2
#cashinvestigation
Toutes l'actualité de Cash Investigation
http://www.francetvinfo.fr/replay-magazine/france-2/cash-investigation/
https://www.facebook.com/cashinvestigationfrance2
Twitter: @cashinvestigati
- published: 22 Sep 2015
- views: 1469
Love you Mom :) -Pokemon ORAS: Not Used Enough #49 - AceTrainerTroy
Breast Cancer Awareness Info: http://healthfinder.gov/nho/octobertoolkit.aspx http://www.astrazeneca-us.com/responsibility/astrazeneca-healthcare-foundation
Wh...
Breast Cancer Awareness Info: http://healthfinder.gov/nho/octobertoolkit.aspx http://www.astrazeneca-us.com/responsibility/astrazeneca-healthcare-foundation
Whats up Trainers Troy back here with Ep. #49 of Not Used Enough. Current Record: 29-31
Smash that Like button to 35 Likes!!
Battle 1 Starts- 5:45
Q&A; Starts- 14:48
Battle 2 Starts- 28:12
▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬
Dont forget to leave any Q&As;, Comments, Likes
Subscribe!
http://tinyurl.com/pxb2agm
▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬
Follow me on twitter where I accept battle challenges
https://twitter.com/acetrainertroy
▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬
Follow me on Twitch
http://www.twitch.tv/acetrainertroy
▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬
Songs Used:
https://www.youtube.com/user/ocremix
Outro Song:
https://www.youtube.com/watch?v=1eXGv_wa7DE
▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬
Donate to AceTrainerTroy
http://bit.ly/1wr8HD1
▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬
GFX done by CoolTrainerJulio:
https://www.youtube.com/user/CoolTrainerJulio
▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬
And As Always ill see you guys Next Time!
wn.com/Love You Mom ) Pokemon Oras Not Used Enough 49 Acetrainertroy
Breast Cancer Awareness Info: http://healthfinder.gov/nho/octobertoolkit.aspx http://www.astrazeneca-us.com/responsibility/astrazeneca-healthcare-foundation
Whats up Trainers Troy back here with Ep. #49 of Not Used Enough. Current Record: 29-31
Smash that Like button to 35 Likes!!
Battle 1 Starts- 5:45
Q&A; Starts- 14:48
Battle 2 Starts- 28:12
▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬
Dont forget to leave any Q&As;, Comments, Likes
Subscribe!
http://tinyurl.com/pxb2agm
▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬
Follow me on twitter where I accept battle challenges
https://twitter.com/acetrainertroy
▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬
Follow me on Twitch
http://www.twitch.tv/acetrainertroy
▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬
Songs Used:
https://www.youtube.com/user/ocremix
Outro Song:
https://www.youtube.com/watch?v=1eXGv_wa7DE
▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬
Donate to AceTrainerTroy
http://bit.ly/1wr8HD1
▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬
GFX done by CoolTrainerJulio:
https://www.youtube.com/user/CoolTrainerJulio
▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬
And As Always ill see you guys Next Time!
- published: 16 Oct 2015
- views: 185